Published in Psychiatry Res on December 15, 2005
Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans. Neuropharmacology (2013) 0.95
Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging (2008) 0.89
Imaging receptor changes in human drug abusers. Curr Top Behav Neurosci (2010) 0.83
No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res (2013) 0.81
Effects of smoking on D₂/D₃ striatal receptor availability in alcoholics and social drinkers. Brain Imaging Behav (2013) 0.79
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.56
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
The risk factors of Internet addiction--a survey of university freshmen. Psychiatry Res (2009) 1.52
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry (2008) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet (2012) 1.47
Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38
Catatonic coma with profound bradycardia. Psychosomatics (2007) 1.38
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet (2009) 1.38
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry (2008) 1.37
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis (2006) 1.32
Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. Schizophr Res (2002) 1.30
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull (2003) 1.30
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res (2005) 1.28
A study on the sleep quality of incoming university students. Psychiatry Res (2012) 1.27
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res (2006) 1.24
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol (2004) 1.23
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res (2005) 1.20
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. Schizophr Res (2006) 1.19
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res (2009) 1.17
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr Serv (2006) 1.12
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv (2006) 1.09
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry (2004) 1.04
Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers--a SPECT study. Neuroimage (2007) 1.04
The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry (2008) 1.02
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol (2008) 1.02
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett (2005) 1.02
Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol (2008) 1.00
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc (2008) 0.96
Greater availability of dopamine transporters in patients with major depression--a dual-isotope SPECT study. Psychiatry Res (2008) 0.95
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry (2002) 0.95
Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.95
Psychiatric morbidity and posttraumatic symptoms among earthquake victims in primary care clinics. Gen Hosp Psychiatry (2003) 0.93
The amygdala excitatory/inhibitory balance in a valproate-induced rat autism model. PLoS One (2013) 0.93
Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects. Clin Schizophr Relat Psychoses (2012) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. Psychiatry Clin Neurosci (2003) 0.92
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med (2008) 0.92
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res (2011) 0.91
High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord (2009) 0.91
The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord (2010) 0.90
Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics (2008) 0.90
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry (2004) 0.89
MAOA interacts with the ALDH2 gene in anxiety-depression alcohol dependence. Alcohol Clin Exp Res (2010) 0.89
Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res (2011) 0.89
Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun (2011) 0.88
The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet (2012) 0.88
The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Res (2008) 0.88
Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls. Psychiatry Res (2003) 0.87
Smoking and psychosis in patients with bipolar I disorder. Compr Psychiatry (2002) 0.87
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry (2009) 0.87
Changes in bone mineral density of lumbar spine after pelvic radiotherapy. Radiother Oncol (2002) 0.87